Theravance Biopharma (TBPH) Competitors $14.44 +0.09 (+0.63%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$14.63 +0.19 (+1.31%) As of 10/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. IMVT, APLS, RARE, HCM, KNSA, OGN, MLYS, ALVO, IBRX, and BHCShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Mineralys Therapeutics (MLYS), Alvotech (ALVO), ImmunityBio (IBRX), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. Theravance Biopharma vs. Its Competitors Immunovant Apellis Pharmaceuticals Ultragenyx Pharmaceutical HUTCHMED Kiniksa Pharmaceuticals International Organon & Co. Mineralys Therapeutics Alvotech ImmunityBio Bausch Health Cos Theravance Biopharma (NASDAQ:TBPH) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends. Does the media favor TBPH or IMVT? In the previous week, Theravance Biopharma had 2 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Theravance Biopharma and 2 mentions for Immunovant. Theravance Biopharma's average media sentiment score of 0.81 beat Immunovant's score of 0.23 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, TBPH or IMVT? Theravance Biopharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Is TBPH or IMVT more profitable? Theravance Biopharma has a net margin of 16.88% compared to Immunovant's net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma16.88% 6.93% 3.52% Immunovant N/A -80.99%-72.23% Do analysts recommend TBPH or IMVT? Theravance Biopharma presently has a consensus target price of $23.00, suggesting a potential upside of 59.28%. Immunovant has a consensus target price of $31.00, suggesting a potential upside of 92.79%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00Immunovant 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has higher earnings & valuation, TBPH or IMVT? Theravance Biopharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M11.30-$56.42M$0.2460.17ImmunovantN/AN/A-$413.84M-$2.85-5.64 Do insiders and institutionals have more ownership in TBPH or IMVT? 99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryTheravance Biopharma beats Immunovant on 13 of the 16 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$722.68M$2.62B$6.09B$10.54BDividend YieldN/A56.71%5.69%4.71%P/E Ratio60.1723.6985.3527.60Price / Sales11.30556.23539.78202.41Price / CashN/A173.2337.9261.55Price / Book4.045.5313.016.76Net Income-$56.42M$32.78M$3.30B$275.88M7 Day Performance2.63%5.82%4.34%2.81%1 Month Performance4.94%13.16%9.49%9.24%1 Year Performance79.16%1.69%84.83%35.42% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma3.4239 of 5 stars$14.44+0.6%$23.00+59.3%+82.1%$722.68M$64.38M60.17110Analyst ForecastIMVTImmunovant1.8768 of 5 stars$16.06-1.0%$33.60+109.2%-45.7%$2.83BN/A-5.64120APLSApellis Pharmaceuticals4.0659 of 5 stars$22.65+1.3%$33.29+47.0%-9.1%$2.83B$781.37M-12.44770Analyst ForecastRAREUltragenyx Pharmaceutical4.387 of 5 stars$30.36+4.4%$81.50+168.4%-42.1%$2.80B$560.23M-5.491,294Analyst ForecastHCMHUTCHMED2.4168 of 5 stars$15.66+0.1%$20.88+33.3%-20.5%$2.73B$630.20M0.001,811Analyst ForecastKNSAKiniksa Pharmaceuticals International3.649 of 5 stars$38.77+6.2%$44.29+14.2%+56.6%$2.70B$423.24M969.49220Analyst DowngradeHigh Trading VolumeOGNOrganon & Co.4.7515 of 5 stars$10.35+1.3%$17.33+67.6%-43.4%$2.65B$6.40B3.854,000Analyst ForecastMLYSMineralys Therapeutics2.7637 of 5 stars$39.35-1.6%$43.50+10.5%+175.7%$2.65BN/A-11.0528Positive NewsAnalyst ForecastALVOAlvotech3.2774 of 5 stars$8.40+0.7%$14.00+66.7%-32.5%$2.51B$560.10M36.521,032Analyst ForecastGap UpIBRXImmunityBio2.6507 of 5 stars$2.57+1.2%$10.75+318.3%-28.1%$2.40B$14.74M-5.35590BHCBausch Health Cos4.7566 of 5 stars$6.47-0.2%$9.00+39.1%-21.1%$2.40B$9.63B24.8920,700Analyst Forecast Related Companies and Tools Related Companies IMVT Alternatives APLS Alternatives RARE Alternatives HCM Alternatives KNSA Alternatives OGN Alternatives MLYS Alternatives ALVO Alternatives IBRX Alternatives BHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
